Funding will not be a problem for us anymore. It’s just the level of dilution that we may need to leave with. We are stronger now than we have ever been.
We also need to remember that the primary end point of the FDA EFS is only 30 days and we could have that by years end or at least Q1 2023. Plus the 12 month data for the first cohort is being presented at London Valves in late November.
Not to mention that we could get Breakthrough Device Designation any day now.
Funding will not be a problem for us anymore. It’s just the...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
0.000(0.00%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 84 | $17.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.55 | 2146 | 3 |
View Market Depth
| Last trade - 15.28pm 23/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |
Day chart unavailable